<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2556">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04355962</url>
  </required_header>
  <id_info>
    <org_study_id>2020-00719</org_study_id>
    <nct_id>NCT04355962</nct_id>
  </id_info>
  <brief_title>Sevoflurane in COVID-19 ARDS (SevCov)</brief_title>
  <official_title>Sevoflurane Sedation in COVID-19 ARDS Patients to Reduce Lung Injury: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kantonsspital Münsterlingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Triemli Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to study the effect of initial temporary sevoflurane sedation on
      mortality and persistent organ dysfunction (POD) in survivors at day 28 after ICU admission
      in the population of patients suffering from COVID-19 ARDS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The corona virus disease 19 (COVID-19) pandemic, caused by the severe acute respiratory
      syndrome corona virus 2 (SARS-CoV-2), is spreading rapidly across Europe. While data from
      European centers are still missing, several publications from Chinese centers are available.
      Respiratory failure from acute respiratory distress syndrome (ARDS) is the leading cause of
      mortality, and may be caused or exacerbated by a 'cytokine storm syndrome'.

      Recent trials from our group demonstrated that the volatile anesthetic sevoflurane
      administered during ventilation of patients has anti-inflammatory properties. Moreover, in in
      vivo studies volatile anesthetics reduce the severity of ARDS compared to intravenous
      sedation, which has been confirmed in a clinical pilot trial. Attenuating ARDS and thereby
      improving oxygenation strongly decreases morbidity and mortality of patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>a randomized, controlled multi-center trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Patients will not be informed about their group assignments, technicians processing the samples will not have any access to the ICU or the patient chart (= double-blind trial). Due to the procedures involved in volatile versus intravenous sedation, group assignment cannot be entirely concealed for the study staff and ICU doctors/nurses involved with the procedure in the ICU (pragmatic limits of blinding).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Composite outcome of death rate (rate of patients that did not survive) and organ failure rate (rate of patients surviving with persistent organ dysfunction) at day 28</measure>
    <time_frame>28 days</time_frame>
    <description>The effect of sevoflurane application on mortality (rate of patients that does not survive 28 days) and persistent organ dysfunction (rate of patients surviving with a persistent organ failure at day 28) will be assessed. Organ failures are defined as pulmonary failure (necessity of ventilation); cardiovascular failure (need of vasopressors), retail failure (need of renal replacement therapy)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay ICU</measure>
    <time_frame>28 days</time_frame>
    <description>The effect of sevoflurane application on the length of stay at ICU will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Inflammatory markers</measure>
    <time_frame>8 days</time_frame>
    <description>The impact of sevoflurane on the course of inflammatory markers will be evaluated (pro-calcitonin, PCT; c-reactive protein, CRP; interleukin 6, IL-6; monocyte chemoattractant protein 1, MCP-1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay at hospital</measure>
    <time_frame>28 days</time_frame>
    <description>The effect of sevoflurane application on the length of stay at hospital will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sex-related differences in complications</measure>
    <time_frame>28 days</time_frame>
    <description>Sex-related differences in complications will be assessed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>ARDS, Human</condition>
  <condition>Coronavirus</condition>
  <arm_group>
    <arm_group_label>Sevoflurane Sedation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sedation with sevoflurane (etSevo 0.5-1.5 Vol %) for 48 hours in patients with COVID-19 ARDS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No use of sevoflurane, but current intravenous sedation at discretion of the ICU physician in charge, e.g. with propofol, fentanyl, midazolam and dexmedetomidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Sedation with sevoflurane (etSevo 0.5-1.5 Vol %) for 48 hours in patients with COVID-19 ARDS</description>
    <arm_group_label>Sevoflurane Sedation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous drug</intervention_name>
    <description>Intravenous sedation in control group will be continued as initiated at the ICU e.g. propofol, fentanyl, midazolam, dexmedetomidine</description>
    <arm_group_label>Intravenous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  SARS-CoV-2 infection (positive testing) or computed tomography (CT) scan-suspected
             COVID-19 ARDS

          -  Male and female patients, age 18 to 85 years

          -  ICU patients with ARDS defined as PaO2/FiO2 &lt; 200mmHg (=26.6kPa)

          -  Time of intubation not longer than 24 hours

          -  Sedation and mechanical ventilation in ICU

          -  Informed consent, signed by a representative or by an independent physician

        Exclusion Criteria:

          -  High dose systemic corticosteroids in the phase before hospitalization (&gt; 10mg/d
             prednisone or equivalent dose)

          -  Significant concomitant disease (acute cerebral vascular event, acute coronary
             syndrome, seizure, burn, neuromuscular disease)

          -  Organ transplant

          -  AIDS

          -  Pregnancy and/or breastfeeding

          -  Use of cytokine absorber
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beatrice Beck Schimmer, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin Schläpfer, PD</last_name>
    <phone>+41442554690</phone>
    <phone_ext>+41442554690</phone_ext>
    <email>martin.schlaepfer@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beatrice Beck Schimmer, Prof</last_name>
    <phone>+41442551111</phone>
    <phone_ext>+41442551111</phone_ext>
    <email>beatrice.beck@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kantonsspital Münsterlingen</name>
      <address>
        <city>Münsterlingen</city>
        <zip>8596</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Neff, PD Dr. med.</last_name>
      <phone>+41 71 686 2108</phone>
      <email>thomas.neff@sec.stgag.ch</email>
    </contact>
    <contact_backup>
      <last_name>Tobias Huebner, Dr. med.</last_name>
      <phone>+41 71 686 2044</phone>
      <email>tobias.huebner@stgag.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Stadtspital Triemli</name>
      <address>
        <city>Zurich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Fodor, KD Dr. med.</last_name>
      <phone>+41 44 4165222</phone>
      <email>patricia.fodor@triemli.zuerich.ch</email>
    </contact>
    <contact_backup>
      <last_name>Sereina Dübendorfer, Dr. med.</last_name>
      <phone>+41 44 416 5202</phone>
      <email>sereina.duebendorfer@triemli.zuerich.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Zuirch</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin H Schläpfer, PD MD</last_name>
      <phone>+41442554690</phone>
      <phone_ext>+41442554690</phone_ext>
      <email>martin.schlaepfer@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.</citation>
    <PMID>32091533</PMID>
  </reference>
  <reference>
    <citation>Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.</citation>
    <PMID>32031570</PMID>
  </reference>
  <reference>
    <citation>Xie J, Tong Z, Guan X, Du B, Qiu H, Slutsky AS. Critical care crisis and some recommendations during the COVID-19 epidemic in China. Intensive Care Med. 2020 May;46(5):837-840. doi: 10.1007/s00134-020-05979-7. Epub 2020 Mar 2.</citation>
    <PMID>32123994</PMID>
  </reference>
  <reference>
    <citation>Suter D, Spahn DR, Blumenthal S, Reyes L, Booy C, Z'graggen BR, Beck-Schimmer B. The immunomodulatory effect of sevoflurane in endotoxin-injured alveolar epithelial cells. Anesth Analg. 2007 Mar;104(3):638-45.</citation>
    <PMID>17312223</PMID>
  </reference>
  <reference>
    <citation>Yue T, Roth Z'graggen B, Blumenthal S, Neff SB, Reyes L, Booy C, Steurer M, Spahn DR, Neff TA, Schmid ER, Beck-Schimmer B. Postconditioning with a volatile anaesthetic in alveolar epithelial cells in vitro. Eur Respir J. 2008 Jan;31(1):118-25. Epub 2007 Sep 26.</citation>
    <PMID>17898018</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 26, 2020</study_first_submitted>
  <study_first_submitted_qc>April 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>ARDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

